SNYR

InnovAge Holding Corp. (INNV) came out with quarterly earnings of $0.06 per share, missing the Zacks Consensus Estimate of $0.09 per share. This compares to a loss of $0.01 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of -33.33%. A quarter ago, it was expected that this company would post earnings of $0.06 per share when it actually produced a loss of $0.22, delivering a surprise of -466.67%. Over the last four quarters, the company has surpassed consensus EPS estimates two times. InnovAge, which belongs to the Zacks Medical Services industry, posted revenues of $261.95 million for the quarter ended June 2026, surpassing the Zacks Consensus Estimate by 9.90%. This compares to year-ago revenues of $221.42 million. The company has topped consensus revenue estimates four times over the last four quarters. The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call. InnovAge shares have added about 107.1% since the beginning of the year versus the S&P 500's gain of 12.8%. While InnovAge has outperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock? There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately. Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions. Ahead of this earnings release, the estimate revisions trend for InnovAge was mixed. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #3 (Hold) for the stock. So, the shares are expected to perform in line with the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. It will be interesting to see how estimates for the coming quarters and the current fiscal year change in the days ahead. The current consensus EPS estimate is $0.12 on $252.65 million in revenues for the coming quarter and $0.50 on $1.04 billion in revenues for the current fiscal year. Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Medical Services is currently in the top 36% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1. Another stock from the same industry, Synergy CHC Corp. (SNYR), has yet to report results for the quarter ended June 2026. This company is expected to post quarterly loss of $0.01 per share in its upcoming report, which represents a year-over-year change of -105.9%. The consensus EPS estimate for the quarter has remained unchanged over the last 30 days. Synergy CHC Corp.'s revenues are expected to be $8.3 million, up 23.2% from the year-ago quarter. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report InnovAge Holding Corp. (INNV) : Free Stock Analysis Report Synergy CHC Corp. (SNYR) : Free Stock Analysis Report This article originally published on Zacks Investment Research (zacks.com). Zacks Investment Research

N. WINDHAM, Maine, May 14, 2026 (GLOBE NEWSWIRE) -- Synergy CHC Corp. (NASDAQ: SNYR) (“Synergy” or the “Company”), a consumer health and wellness company, is announcing its financial results for the three months ended March 31, 2026. “Our first quarter results reflect continued execution and the growing momentum of our functional beverage business,” said Jack Ross, CEO of Synergy CHC Corp. “During the quarter, we generated over $650,000 in functional beverage revenue, exceeding our total beverage revenue for all of 2025. This performance reflects the success of our expanding retail and distribution partnerships across the U.S., supported by healthy sell-through that is already driving increased reorder activity. Reflecting this momentum, our beverage division is operating at an estimated annual run rate exceeding $4 million. With this foundation in place and continued expansion of our distribution footprint underway, we believe we are well-positioned to capture the significant growth opportunities emerging within the functional beverage sector. With solid early-year momentum and a clear strategic path, we expect 2026 to be a year of sustainable growth and value creation for our shareholders.” First Quarter 2026 Financial Summary vs. Same Year-Ago Period Revenue of $5.49 million vs. $8.17 million. Gross margin of 72.3% vs. 75.4%. Income (loss) from operations of ($0.57) million vs. $1.95 million. Net income (loss) of ($2.57) million vs. $0.88 million. Earnings (loss) per share of ($0.23) vs. $0.10. EBITDA (loss), a non-GAAP financial measure, was ($0.54) million vs. $1.98 million. Adjusted EBITDA (loss), a non-GAAP financial measure, was $(0.35) million vs. $1.98 million. First Quarter 2026 Financial Results Revenue in the first quarter of 2026 was $5.49 million compared to $8.17 million in the first quarter of 2025, due to license revenue of $1.5 million in 2025 that did not repeat in 2026 and out-of-stock dynamics for several key online items in our Flat Tummy brand, which impacted online sales. This was partially offset by strong performance in beverages, which delivered significantly higher revenue compared to the prior year period. Gross margin in the first quarter of 2026 was 72.3% compared to 75.4% in the first quarter of 2025. Excluding license revenue from the first quarter of 2025, normalized gross margin for that period was 70.0%, a 2.3% improvement year-over-year. Operating expenses in the first quarter of 2026 were $4.54 million compared to $4.22 million in the first quarter of 2025, reflecting higher overhead associated with the expansion of the beverage business. Income (loss) from operations for the first quarter of 2026 was ($0.57) million compared to $1.95 million in the first quarter of 2025, which is largely due to the license revenue of $1.5 million in 2025 that did not repeat in 2026 and increased overhead costs. Net income (loss) in the first quarter of 2026 was ($2.57) million compared to net income of $0.88 million in the first quarter of 2025. Earnings (loss) per share in the first quarter of 2026 was ($0.23) compared to $0.10 in the first quarter of 2025. EBITDA (loss) (a non-GAAP financial measure) in the first quarter of 2026 was ($0.54) million compared to $1.98 million in the first quarter of 2025. Adjusted EBITDA (loss) (a non-GAAP financial measure) in the first quarter of 2026 was $(0.35) million compared to $1.98 million in the first quarter of 2025. Balance Sheet and Cash Flow As of March 31, 2026, Synergy had approximately $0.30 million in cash and cash equivalents, compared to $2.6 million in cash and cash equivalents as of December 31, 2025. Subsequent to quarter-end, Synergy raised approximately $2.7 million in gross proceeds through its at-the-market (ATM) equity offering program. As of March 31, 2026, Synergy had a working capital deficit of $0.50 million, compared to a $1.78 million working capital surplus as of December 31, 2025. As of March 31, 2026, Synergy had $3.4 million in inventory, compared to $3.7 million in inventory as of December 31, 2025. Cash used in operating activities for the three months ended March 31, 2026 was $2.0 million compared to cash used in operating activities of $0.82 million for the three months ended March 31, 2025. Non-GAAP Financial Measure Reconciliation: EBITDA and Adjusted EBITDA To assist financial statement users in an assessment of our historical performance, the Company discloses non-GAAP financial measures in press releases and on investor conference calls and related events, as the Company believes that the non-GAAP information enhances investors' overall understanding of our financial performance, and should be read in addition to, rather than instead of, the financial statements prepared in accordance with GAAP. Management believes EBITDA and Adjusted EBITDA provide useful information to investors by excluding certain items that may not be indicative of the Company’s core operating results and that can vary significantly between periods. EBITDA is defined as net income plus interest expense, income tax expense, depreciation and amortization. Adjusted EBITDA is calculated as EBITDA plus or minus foreign exchange gains or losses, one-time expenses and non-cash expenses. Since Adjusted EBITDA is a non-GAAP financial performance measure, the Company’s calculation of Adjusted EBITDA may not be comparable to other similarly titled measures of other companies; and should not be considered in isolation, as a substitute for, or superior to measures of financial performance prepared in accordance with GAAP. The following table reconciles net income to EBITDA and Adjusted EBITDA (in millions of US dollars): About Synergy CHC Corp. Synergy CHC Corp. develops and markets consumer health and wellness products, led by its flagship brands FOCUSfactor® and Flat Tummy®. FOCUSfactor®, a clinically studied brain health supplement and functional beverage line with a 25-year legacy, enjoys established distribution in the U.S., Canada and Mexico. through major retailers including Costco, Walmart, Amazon, BJ's, and Walgreens, among others. Flat Tummy® complements Synergy's portfolio as a lifestyle brand focused on women's wellness and weight management. Forward Looking Statements Certain statements contained in this press release constitute "forward-looking statements," including statements regarding brand expansion and growth initiatives. These forward-looking statements represent Synergy's expectations or beliefs concerning future events, and it is possible that the results described in this press release will not be achieved. These forward-looking statements are subject to risks, uncertainties and other factors, which are set forth in Synergy's registration statement on Form S-1, as amended, many of which are outside of Synergy's control, that could cause actual results to differ materially from the results discussed in the forward-looking statements. Any forward-looking statement speaks only as of the date on which it is made, and, except as required by law, Synergy does not undertake any obligation to update or revise any forward-looking statement, whether as a result of new information, future events or otherwise. New factors emerge from time to time, and it is not possible for Synergy to predict all such factors. When considering these forward-looking statements, you should keep in mind the risk factors and other cautionary statements in Synergy’s filings with the SEC. The risk factors and other factors noted in Synergy's filings could cause its actual results to differ materially from those contained in any forward-looking statement. Investor Relations Gateway Group Cody Slach, Greg Robles 949.574.3860 [email protected]

Management characterized 2025 as a transitional year defined by strategic groundwork in international markets and the beverage sector despite significant one-time financial impacts. The termination of a licensing agreement in the UAE and Turkey, driven by regional macro instability, necessitated a $2.5 million revenue reversal but did not change management's long-term conviction in international demand. The Beverage division is positioned as a primary 2026 growth engine, with Q1 2026 gross revenue already surpassing the entirety of 2025 following the resolution of inventory production delays. The Flat Tummy brand continues to face structural declines as the weight loss category shifts heavily toward GLP-1 medications, prompting a pending strategic review of the asset. Management attributed the lack of same-store growth in the supplement business to the absence of TV advertising, which they identified as a critical competitive necessity for retail performance. Operational expansion in Mexico via a new wholly owned subsidiary has successfully initiated shipments to Costco Mexico, serving as a template for direct retail network building. Reinstating TV advertising is the top operational priority for 2026, with management modeling at least a 15% lift in same-store sales based on historical performance trends. The Beverage division is projected to reach a $2.5 million revenue run rate in 2026, supported by millions of units in stock and new distribution through major convenience and wholesale partners. International growth will focus on executing existing initiatives in Mexico and pursuing capital-efficient, scalable expansion in other markets through licensing. Management expects normalized gross margins to remain stable or increase as the business moves past one-time items such as inventory write-offs, while operating expenses are expected to normalize following the 2025 bad debt allowances. Upcoming retail catalysts include scheduled roadshows at Costco and BJ's Wholesale Club to drive volume for the functional beverage portfolio. Financial results were heavily skewed by $11.5 million in one-time charges, including a $6.66 million bad debt allowance and a $2.9 million license revenue reversal. A $1.04 million write-off for obsolete inventory and a $0.9 million write-off of prepaid media credits further impacted the Q4 operating loss. Professional fees related to corporate development activities significantly increased operating expenses beyond historical normalized levels. The company achieved a working capital surplus of $1.78 million at year-end, a notable improvement from the $1.12 million deficit in the prior year. Our analysts just identified a stock with the potential to be the next Nvidia. Tell us how you invest and we'll show you why it's our #1 pick. Tap here. Management explained that low 2025 beverage revenue was due to the 8-12 week lead time required to build inventory after securing funding in August. The majority of RTD (Ready-to-Drink) inventory only arrived in December, shifting the primary sales impact to early 2026. Management acknowledged the brand is struggling as the industry moves toward GLP-1 drugs. A strategic decision regarding the future of the Flat Tummy business line is expected in the near future. The company confirmed it has no immediate plans to open additional international subsidiaries beyond Mexico. The focus remains on executing within the newly established Mexican retail network rather than spreading resources across new direct markets. One stock. Nvidia-level potential. 30M+ investors trust Moby to find it first. Get the pick. Tap here.

This article first appeared on GuruFocus. Fourth Quarter Net Revenue: $6.07 million, a 41% decrease from the prior year. Adjusted Fourth Quarter Net Revenue: $8.97 million, a 12.7% decrease without the license agreement reversal. Fourth Quarter Gross Margin: 36.6%, down from 63.3% in the prior year. Adjusted Fourth Quarter Gross Margin: 68.8% without one-time items. Fourth Quarter Operating Expenses: $15.53 million, up from $5.14 million in the prior year. Adjusted Fourth Quarter Operating Expenses: $8 million without one-time items. Fourth Quarter Loss from Operations: $13.31 million compared to income of $1.35 million in the prior year. Adjusted Fourth Quarter Loss from Operations: $1.85 million without one-time items. Fourth Quarter Net Loss: $14.82 million or $1.35 per diluted share. Adjusted Fourth Quarter Net Loss: $3.35 million without one-time items. Fourth Quarter EBITDA Loss: $13.28 million compared to EBITDA income of $1.68 million in the prior year. Adjusted Fourth Quarter EBITDA Loss: $4.48 million. Full Year Revenue: $30.38 million, down from $34.83 million in the prior year. Adjusted Full Year Revenue: $33.28 million without license revenue reversal. Full Year Gross Margin: 66.8%, slightly down from 67.9% in the prior year. Adjusted Full Year Gross Margin: 70.3% without inventory write-off. Full Year Operating Expenses: $28.76 million, up from $17.84 million in the prior year. Adjusted Full Year Operating Expenses: $21.24 million without one-time items. Full Year Loss from Operations: $8.46 million compared to income of $5.8 million in the prior year. Adjusted Full Year Income from Operations: $3 million without one-time items. Full Year Net Loss: $12.3 million or $1.27 per diluted share. Adjusted Full Year Net Loss: $3.03 million without one-time items. Full Year EBITDA Loss: $6.19 million compared to EBITDA of $6.46 million in the prior year. Adjusted Full Year EBITDA Income: $800,000. Cash and Cash Equivalents: $2.6 million as of December 31, 2025. Inventory: $3.7 million at the end of the fourth quarter. Total Liabilities: $33.3 million as of December 31, 2025. Working Capital Surplus: $1.78 million as of December 31, 2025. Cash Used in Operating Activities: $2.6 million for the year ended December 31, 2025. Warning! GuruFocus has detected 4 Warning Signs with SNYR. Is SNYR fairly valued? Test your thesis with our free DCF calculator. Release Date: April 01, 2026 For the complete transcript of the earnings call, please refer to the full earnings call transcript. Synergy CHC Corp (NASDAQ:SNYR) established a wholly owned subsidiary in Mexico and initiated product shipments to Costco, Mexico, indicating international expansion. The company generated over $600,000 in gross revenue from its beverage division in the first quarter of 2026, surpassing the entire 2025 revenue. Synergy CHC Corp (NASDAQ:SNYR) has millions of cans of RTDs and shots in stock and ready to ship, positioning the company for growth in its Beverage division. The company successfully shipped three new SKUs to all 1,600 Kroger locations, expanding its retail presence. Synergy CHC Corp (NASDAQ:SNYR) improved its cash position, with cash and cash equivalents increasing to $2.6 million as of December 31, 2025, compared to $687,900 the previous year. The termination of the international license agreement for UAE and Turkey resulted in a $2.5 million revenue reversal, impacting financial results. Net revenue for the fourth quarter decreased by 41% compared to the previous year, primarily due to the license agreement termination. Gross margin for the fourth quarter dropped significantly to 36.6% from 63.3% in the same quarter last year, affected by the license agreement termination and inventory write-offs. Operating expenses increased substantially to $15.53 million in the fourth quarter, driven by one-time items such as bad debt allowance and prepaid media credit write-offs. The company reported a net loss of $14.82 million for the fourth quarter, a significant decline from the net income of $105,700 in the fourth quarter of 2024. Q: What affected the RTD sales in the fourth quarter, and why weren't they higher? A: Jack Ross, CEO, explained that the delay was due to the time required to build inventory after raising funds in August. The inventory was only received in December, impacting fourth-quarter sales. Q: Was there any growth in the Flat Tummy product line compared to the third quarter? A: Jack Ross, CEO, stated that Flat Tummy continues to decline due to the industry's shift towards GLP1s, and a strategic decision on the product line will be made soon. Q: How is the core supplement group performing? A: Jack Ross, CEO, mentioned that the core supplement group remains strong, with new retailers like Kroger onboard. However, TV advertising is crucial for same-store growth, and efforts are underway to resume it. Q: What is the outlook for gross margin after the one-time items are behind? A: Jaime Fickett, CFO, anticipates that gross margin will maintain or increase, excluding the impact of one-time items, as the underlying margin remains stable. Q: Are there plans to expand into other international markets with subsidiaries like in Mexico? A: Jack Ross, CEO, stated there are no current plans to open subsidiaries in other international markets. The focus is on executing existing initiatives, including expanding the retail network in Mexico. For the complete transcript of the earnings call, please refer to the full earnings call transcript.

NORTH WINDHAM, Maine, April 01, 2026 (GLOBE NEWSWIRE) -- Synergy CHC Corp. (NASDAQ: SNYR) (“Synergy” or the “Company”), a consumer health and wellness company, is announcing its financial results for the three and twelve months ended December 31, 2025. “Our full year results reflect a year of meaningful strategic progress and continued advancement of our priority growth initiatives,” said Jack Ross, CEO of Synergy CHC Corp. “During 2026 on the beverage side, we have shipped our Focus and Energy RTDs and shots into several new key distribution partners, including EG America, Wakefern Food, and Pine State Beverage, to name a few. With millions of cans of RTDs and shots in stock and ready to ship, we believe 2026 will be a foundational year for scaling the beverage division and expanding our national footprint. In fact, through the first quarter of 2026, we’ve already generated over $600,000 in gross revenue, nearly matching our full year 2025 performance. This equates to an annualized run rate of approximately $2.5 million, reflecting the meaningful progress we’ve made in expanding our functional beverage distribution.” “In addition, due to instability in the Middle East, we agreed to cancel a licensing agreement with our regional partner. However, we continue to view this as an attractive long-term growth opportunity and intend to revisit this once conditions in the region stabilize. With a more focused portfolio, expanding retail and DSD partnerships, and growing consumer momentum, we believe Synergy is well positioned to drive sustainable growth in the quarters ahead.” Fourth Quarter 2025 Financial Summary vs. Same Year-Ago Period Revenue of $6.07 million vs. $10.27 million. Gross margin of 36.6% vs. 63.3%. Income (loss) from operations of ($13.31) million vs. $1.35 million. Net income (loss) of ($14.82) million vs. $105.7 thousand. Earnings (loss) per share of ($1.35) vs. $0.01. EBITDA (loss), a non-GAAP financial measure, was ($13.28) million vs. $1.68 million. Adjusted EBITDA (loss), a non-GAAP financial measure, was $(4.48) million vs. $2.79 million. 2025 Financial Summary vs. Same Year-Ago Period Revenue of $30.38 million vs. $34.83 million. Gross margin of 66.8% vs. 67.9%. Income (loss) from operations of ($8.46) million vs. $5.80 million. Net income (loss) of ($12.34) million vs. $2.12 million. Earnings (loss) per share of ($1.27) vs. $0.28. EBITDA (loss), a non-GAAP financial measure, was ($6.19) million vs. $6.46 million. Adjusted EBITDA, a non-GAAP financial measure, was $800 thousand vs. $7.35 million. Fourth Quarter and Full Year 2025 Financial Results Revenue in the fourth quarter of 2025 was $6.07 million compared to $10.27 million in the fourth quarter of 2024, due to the termination of the license of $2.9 million. For the full year 2025, revenue was $30.38 million compared to $34.83 million in 2024, due to the termination of license agreement of $2.9 million. Gross margin in the fourth quarter of 2025 was 36.6% compared to 63.3% in the fourth quarter of 2024 due to the termination of license agreement of $2.9 million and a write off of obsolete inventory of $1.04 million. Without those two items, gross margin would have been 68.8%. For the full year 2025, gross margin was 66.8% compared to 67.9% in 2024. Operating expenses in the fourth quarter of 2025 were $15.53 million compared to $5.14 million in the fourth quarter of 2024. This is largely due to one-time items of an allowance for bad debt of $6.66 million and the write off of prepaid media credits of $0.9 million. Without those two items, operating expenses would have been $8.00 million. For the full year 2025, operating expenses were $28.76 million compared to $17.84 million in 2024, which is also due to the above-mentioned one-time items. Without those two items, operating expenses would have been $21.24 million. Income (loss) from operations for the fourth quarter of 2025 was ($13.31) million compared to $1.35 million in the fourth quarter of 2024. This is largely due to one-time items of allowance for bad debt of $6.66 million, termination of license agreement of $2.9 million, write off of obsolete inventory of $1.04 million and write off of prepaid media credits of $0.9 million. Without those one-time items, loss from operations would have been $(1.85) million. For the full year 2025, income (loss) from operations was ($8.46) million compared to $5.80 million in 2024, which is also due to the items listed above. Without those one-time items, the full year income from operations would have been $3.0 million. Net income (loss) in the fourth quarter of 2025 was ($14.82) million compared to net income of $105.7 thousand in the fourth quarter of 2024. This is largely due to one-time items of allowance for bad debt of $6.66 million, termination of license agreement of $2.9 million, write off of obsolete inventory of $1.04 million and write off of prepaid media credits of $0.9 million. Without those one-time items, net loss would have been $(3.35) million. For the full year 2025, net income (loss) was ($12.34) million compared to $2.12 million in 2024, which is also due to the items listed above offset by a gain on the settlement of notes payable of $2.15 million. Without those one-time items, the full year net loss would have been $(3.03) million. Earnings (loss) per share in the fourth quarter of 2025 was ($1.35) compared to $0.01 in the fourth quarter of 2024. For the full year 2025, earnings (loss) per share was ($1.27) compared to $0.28 in 2024. EBITDA (loss) (a non-GAAP financial measure) in the fourth quarter of 2025 was ($13.28) million compared to $1.68 million in the fourth quarter of 2024. For the full year 2025, EBITDA (loss) was ($6.19) million compared to $6.46 million in 2024. Adjusted EBITDA (loss) (a non-GAAP financial measure) in the fourth quarter of 2025 was $(4.48) million compared to $2.79 million in the fourth quarter of 2024. For the full year 2025, Adjusted EBITDA was $800 thousand compared to $7.35 million in 2024. Balance Sheet and Cash Flow As of December 31, 2025, Synergy had approximately $2.6 million in cash and cash equivalents, compared to $687.9 thousand in cash and cash equivalents as of December 31, 2024. As of December 31, 2025, Synergy had a working capital surplus of $1.78 million, compared to a $1.12 million working capital deficit as of December 31, 2024. As of December 31, 2025, Synergy had $3.7 million in inventory, compared to $1.7 million in inventory as of December 31, 2024. Cash used in operating activities for the twelve months ended December 31, 2025 was $2.6 million compared to cash used in operating activities of $4.8 million for the twelve months ended December 31, 2024. Non-GAAP Financial Measure Reconciliation: EBITDA and Adjusted EBITDA To assist financial statement users in an assessment of our historical performance, the Company discloses non-GAAP financial measures in press releases and on investor conference calls and related events, as the Company believes that the non-GAAP information enhances investors' overall understanding of our financial performance, and should be read in addition to, rather than instead of, the financial statements prepared in accordance with GAAP. Management believes EBITDA and Adjusted EBITDA provide useful information to investors by excluding certain items that may not be indicative of the Company’s core operating results and that can vary significantly between periods. EBITDA is defined as net income plus interest expense, income tax expense, depreciation and amortization. Adjusted EBITDA is calculated as EBITDA plus or minus foreign exchange gains or losses, one-time expenses and non-cash expenses. Since Adjusted EBITDA is a non-GAAP financial performance measure, the Company’s calculation of Adjusted EBITDA may not be comparable to other similarly titled measures of other companies; and should not be considered in isolation, as a substitute for, or superior to measures of financial performance prepared in accordance with GAAP. The following table reconciles net income to EBITDA and Adjusted EBITDA (in millions of US dollars): Conference Call In conjunction with this announcement, Synergy will host a conference call at 9:00 a.m. ET / 6:00 a.m. PT on April 1, 2026, with the Company’s Chief Executive Officer, Jack Ross, and the Company’s Chief Financial Officer, Jaime Fickett. A live webcast of the call will be available on the Investor Relations section of Synergy’s website. To access the call by phone, please register here and you will be provided with dial in details. To avoid delays, we encourage participants to dial into the conference call 15 minutes ahead of the scheduled start time. A replay of the webcast will also be available for a limited time on the Company’s website. About Synergy CHC Corp. Synergy CHC Corp. develops and markets consumer health and wellness products, led by its flagship brands FOCUSfactor® and Flat Tummy®. FOCUSfactor®, a clinically studied brain health supplement and functional beverage line with a 25-year legacy, enjoys established distribution in the U.S., Canada and Mexico. through major retailers including Costco, Walmart, Amazon, BJ's, and Walgreens, among others. Flat Tummy® complements Synergy's portfolio as a lifestyle brand focused on women's wellness and weight management. Forward Looking Statements Certain statements contained in this press release constitute "forward-looking statements," including statements regarding brand expansion and growth initiatives. These forward-looking statements represent Synergy's expectations or beliefs concerning future events, and it is possible that the results described in this press release will not be achieved. These forward-looking statements are subject to risks, uncertainties and other factors, which are set forth in Synergy's registration statement on Form S-1, as amended, many of which are outside of Synergy's control, that could cause actual results to differ materially from the results discussed in the forward-looking statements. Any forward-looking statement speaks only as of the date on which it is made, and, except as required by law, Synergy does not undertake any obligation to update or revise any forward-looking statement, whether as a result of new information, future events or otherwise. New factors emerge from time to time, and it is not possible for Synergy to predict all such factors. When considering these forward-looking statements, you should keep in mind the risk factors and other cautionary statements in Synergy’s filings with the SEC. The risk factors and other factors noted in Synergy's filings could cause its actual results to differ materially from those contained in any forward-looking statement. Investor Relations Gateway Group Cody Slach, Greg Robles 949.574.3860 [email protected]

HealthEquity (HQY) came out with quarterly earnings of $0.95 per share, beating the Zacks Consensus Estimate of $0.89 per share. This compares to earnings of $0.69 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of +7.09%. A quarter ago, it was expected that this provider of services for managing health care accounts would post earnings of $0.9 per share when it actually produced earnings of $1.01, delivering a surprise of +12.22%. Over the last four quarters, the company has surpassed consensus EPS estimates four times. HealthEquity, which belongs to the Zacks Medical Services industry, posted revenues of $334.59 million for the quarter ended January 2026, surpassing the Zacks Consensus Estimate by 0.52%. This compares to year-ago revenues of $311.82 million. The company has topped consensus revenue estimates four times over the last four quarters. The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call. HealthEquity shares have lost about 14.1% since the beginning of the year versus the S&P 500's decline of 2.1%. While HealthEquity has underperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock? There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately. Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions. Ahead of this earnings release, the estimate revisions trend for HealthEquity was mixed. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #3 (Hold) for the stock. So, the shares are expected to perform in line with the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. It will be interesting to see how estimates for the coming quarters and the current fiscal year change in the days ahead. The current consensus EPS estimate is $1.15 on $355.32 million in revenues for the coming quarter and $4.58 on $1.39 billion in revenues for the current fiscal year. Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Medical Services is currently in the bottom 43% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1. One other stock from the same industry, Synergy CHC Corp. (SNYR), is yet to report results for the quarter ended December 2025. This company is expected to post quarterly earnings of $0.01 per share in its upcoming report, which represents no change from the year-ago quarter. The consensus EPS estimate for the quarter has remained unchanged over the last 30 days. Synergy CHC Corp.'s revenues are expected to be $11.05 million, up 7.3% from the year-ago quarter. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report HealthEquity, Inc. (HQY) : Free Stock Analysis Report Synergy CHC Corp. (SNYR) : Free Stock Analysis Report This article originally published on Zacks Investment Research (zacks.com). Zacks Investment Research

This article first appeared on GuruFocus. Net Revenue: $8 million, up 12.4% from $7.1 million in Q3 2024. Gross Margin: 70.9%, compared to 67.2% in Q3 2024. Operating Expenses: $4.4 million, up from $3.7 million in Q3 2024. Income from Operations: $1.28 million, up 21.8% from $1.05 million in Q3 2024. Net Income: $125.3 thousand, compared to $783.6 thousand in Q3 2024. Earnings Per Share: $0.01 per diluted share, compared to $0.11 per diluted share in Q3 2024. Adjusted EBITDA Per Share: $0.15 per diluted share, compared to $0.18 per diluted share in Q3 2024. EBITDA: $1.31 million, down 1.3% from $1.33 million in Q3 2024. Adjusted EBITDA: $1.52 million, up 13.4% from $1.34 million in Q3 2024. Cash and Cash Equivalents: $1 million as of September 30, 2025, compared to $687.9 thousand as of December 31, 2024. Inventory: $2.1 million as of September 30, 2025, compared to $1.7 million as of December 31, 2024. Working Capital: Surplus of $16.68 million as of September 30, 2025, compared to a deficit of $1.12 million as of December 31, 2024. Cash Used in Operating Activities: $3.21 million for the nine months ended September 30, 2025, compared to $1.38 million for the same period in 2024. Warning! GuruFocus has detected 4 Warning Signs with SNYR. Is SNYR fairly valued? Test your thesis with our free DCF calculator. Release Date: November 13, 2025 For the complete transcript of the earnings call, please refer to the full earnings call transcript. Synergy CHC Corp (NASDAQ:SNYR) reported its 11th consecutive quarter of profitability, demonstrating consistent operational discipline. Revenue, gross profit, and income from operations increased year over year, highlighting the company's growth and scalability. The company made significant leadership additions, including Teresa Thompson and Bob Anderson, to support expanding operations and distribution. Synergy CHC Corp (NASDAQ:SNYR) secured major distribution wins, expanding its retail availability for functional beverages both nationally and internationally. Focus Factor was named the number one pharmacist recommended OTC memory supplement for 2025-2026, reinforcing brand confidence and market position. Net income for the third quarter decreased to $125.3 thousand from $783.6 thousand in the same quarter last year. Earnings per share dropped to $0.01 per diluted share from $0.11 per diluted share year over year. Operating expenses increased to $4.4 million from $3.7 million, primarily due to costs associated with being a public company and launching the beverage division. Cash used in operating activities increased to $3.21 million for the nine months ended September 30, 2025, compared to $1.38 million in the previous year. The company anticipates higher general and administrative expenses in the upcoming quarters due to additional human capital required for expanding distribution networks. Q: Can you give us some sense of what contribution there was in the quarter from the beverages? A: Jack Ross, CEO: In the current quarter, the third quarter, there was $159,000 of beverage revenue. Q: Can you provide more color on the dynamics of the product mix, specifically the highest margin revenue source? A: Jack Ross, CEO: In our supplement business, we took an 11% price increase to our Costco business. Our gross margin on supplements was about 75% before, and this increase has improved it further. Our gross to net difference is about 11%. Q: Is the G&A reported in the quarter indicative of what we should expect ongoing, or will it be higher due to executive additions? A: Jack Ross, CEO: We have added a secondary strategy to our beverage rollout, which involves adding human capital to support DSD distributors. This will result in increased G&A in the fourth quarter and beyond as we expand our distribution network. Q: What are the plans for expanding the beverage business given the recent distribution opportunities? A: Jack Ross, CEO: We are rapidly signing DSD networks and expect to have an all-state strategy soon. This expansion will be supported by additional sales and service personnel to accelerate our RTD business in convenience stores. Q: How is the company positioned for future growth following recent developments? A: Jack Ross, CEO: 2025 has been foundational, with debt refinancing, equity raising, and key partnerships. We are well-positioned for an exciting 2026, with over 3 million cans of drink inventory and ongoing production. For the complete transcript of the earnings call, please refer to the full earnings call transcript.

WESTBROOK, Maine, Nov. 13, 2025 (GLOBE NEWSWIRE) -- Synergy CHC Corp. (NASDAQ: SNYR) (“Synergy” or the “Company”), a leading consumer health and wellness company, is announcing its financial results for the three months ended September 30, 2025. “We are pleased to report our 11th quarter of profitability and double-digit revenue growth, accompanied by over 300 basis points of gross margin expansion,” said Jack Ross, CEO of Synergy CHC Corp. “We made meaningful progress across our strategic priorities by expanding retail authorizations and distribution partnerships for our FOCUSfactor functional beverages and shots. Key partnerships with leading retailers, including Kroger and Wakefern, are strengthening our reach across North America. Additionally, we completed a $4.4 million public offering in August, providing us with added working capital to support continued growth and brand expansion. With this added flexibility, along with our retail and distribution efforts, we’re well positioned for growth in the fourth quarter and beyond, which we believe will create meaningful value for our shareholders.” Third Quarter 2025 Financial Summary vs. Same Year-Ago Period Revenue of $8.0 million vs. $7.1 million. Gross margin of 70.9% vs. 67.2%. Income from operations of $1.28 million vs. $1.05 million. Net income of $125.3 thousand vs. $783.6 thousand. Earnings per share of $0.01 vs. $0.11. EBITDA, a non-GAAP financial measure, was $1.31 million vs. $1.33 million. Adjusted EBITDA, a non-GAAP financial measure, was $1.52 million vs. $1.34 million. Adjusted EBITDA per share, a non-GAAP financial measure, was $0.15 vs. $0.18. Recent Business Highlights Synergy recently announced multiple new retail and distribution wins for its FOCUSfactor supplements and beverages, including placements with Kroger and Wakefern, along with regional partnerships with EG America, AlaBev and Atlantic Importing. These agreements expand FOCUSfactor’s U.S. footprint across grocery, pharmacy and convenience channels. On August 27, 2025, Synergy announced the completion of its $4.4 million underwritten public offering of common stock, providing additional working capital to support continued growth initiatives. On September 22, 2025, Synergy appointed former Costco executive Teresa Thompson to the Board of Directors, strengthening the Company’s retail and consumer health expertise. During the third quarter, the Company reduced outstanding liabilities by $3.3 million. Subsequent to quarter end, Synergy announced that FOCUSfactor was named the #1 Pharmacist Recommended OTC Memory Supplement for 2025-2026 by Pharmacy Times, underscoring the brand’s category leadership and continued consumer and professional trust. Third Quarter 2025 Financial Results Revenue in the third quarter of 2025 was $8.0 million, up 12.4% compared to $7.1 million in the third quarter of 2024. Gross margin in the third quarter of 2025 was 70.9% compared to 67.2% in the third quarter of 2024. The increase was largely driven by a favorable shift in product mix. Operating expenses in the third quarter of 2025 were $4.4 million, up 17.7% compared to $3.7 million in the third quarter of 2024. The increase was primarily driven by incremental costs associated with being a public company and the added costs of launching the Company’s beverage division. Income from operations for the third quarter of 2025 was $1.28 million, up 21.8% compared to $1.05 million in the third quarter of 2024. The increase in operating income was due to the improvement in gross margin. Net income in the third quarter of 2025 was $125.3 thousand compared to net income of $783.6 thousand in the third quarter of 2024. Earnings per share in the third quarter of 2025 was $0.01 compared to $0.11 in the third quarter of 2024. EBITDA (a non-GAAP financial measure) in the third quarter of 2025 was $1.31 million compared to $1.33 million in the third quarter of 2024. Adjusted EBITDA (a non-GAAP financial measure) in the third quarter of 2025 was $1.52 million, up 13.4% compared to $1.34 million in the third quarter of 2024. Adjusted EBITDA per share (a non-GAAP financial measure) in the third quarter was $0.15 compared to $0.18 in the third quarter of 2024. Balance Sheet and Cash Flow As of September 30, 2025, Synergy had approximately $1.0 million in cash and cash equivalents, compared to $687.9 thousand in cash and cash equivalents as of December 31, 2024. As of September 30, 2025, Synergy had a working capital surplus of $16.68 million, compared to a $1.12 million working capital deficit as of December 31, 2024. As of September 30, 2025, Synergy had $2.1 million in inventory, compared to $1.7 million in inventory as of December 31, 2024. Cash used in operating activities for the nine months ended September 30, 2025 was $3.21 million compared to cash used in operating activities of $1.38 million for the nine months ended September 30, 2024. The increase was primarily attributable to a reduction in the Company’s liabilities and higher inventory investment to launch its beverage division. Non-GAAP Financial Measure Reconciliation: EBITDA and Adjusted EBITDA To assist financial statement users in an assessment of our historical performance, the Company discloses non-GAAP financial measures in press releases and on investor conference calls and related events, as the Company believes that the non-GAAP information enhances investors' overall understanding of our financial performance, and should be read in addition to, rather than instead of, the financial statements prepared in accordance with GAAP. Management believes EBITDA and Adjusted EBITDA provide useful information to investors by excluding certain items that may not be indicative of the Company’s core operating results and that can vary significantly between periods. EBITDA is defined as net income plus interest expense, income tax expense, depreciation and amortization. Adjusted EBITDA is calculated as EBITDA plus or minus foreign exchange gains or losses and non-cash expenses. The following table reconciles net income to EBITDA and Adjusted EBITDA (in millions of US dollars): Conference Call In conjunction with this announcement, Synergy will host a conference call at 9:00 a.m. ET / 6:00 a.m. PT on November 13, 2025, with the Company’s Chief Executive Officer, Jack Ross, and the Company’s Chief Financial Officer, Jaime Fickett. A live webcast of the call will be available on the Investor Relations section of Synergy’s website. To access the call by phone, please register here and you will be provided with dial in details. To avoid delays, we encourage participants to dial into the conference call 15 minutes ahead of the scheduled start time. A replay of the webcast will also be available for a limited time on the Company’s website. About Synergy CHC Corp. Synergy CHC Corp. develops and markets consumer health and wellness products, led by its flagship brands FOCUSfactor® and Flat Tummy®. FOCUSfactor®, a clinically studied brain health supplement and functional beverage line with a 25-year legacy, enjoys established distribution in the U.S., Canada, and the U.K. through major retailers including Costco, Walmart, Amazon, BJ's, and Walgreens, among others. The brand continues to accelerate growth, penetrating new markets both domestically and internationally, with recent retail wins across mass, grocery, pharmacy, convenience, and wholesale channels poised to drive meaningful gains in late 2025. Flat Tummy® complements Synergy's portfolio as a lifestyle brand focused on women's wellness and weight management. Forward Looking Statements Certain statements contained in this press release constitute "forward-looking statements," including statements regarding brand expansion and growth initiatives. These forward-looking statements represent Synergy's expectations or beliefs concerning future events, and it is possible that the results described in this press release will not be achieved. These forward-looking statements are subject to risks, uncertainties and other factors, which are set forth in Synergy's registration statement on Form S-1, as amended, many of which are outside of Synergy's control, that could cause actual results to differ materially from the results discussed in the forward-looking statements. Any forward-looking statement speaks only as of the date on which it is made, and, except as required by law, Synergy does not undertake any obligation to update or revise any forward-looking statement, whether as a result of new information, future events or otherwise. New factors emerge from time to time, and it is not possible for Synergy to predict all such factors. When considering these forward-looking statements, you should keep in mind the risk factors and other cautionary statements in Synergy’s filings with the SEC. The risk factors and other factors noted in Synergy's filings could cause its actual results to differ materially from those contained in any forward-looking statement. Investor Relations Gateway Group Cody Slach, Greg Robles 949.574.3860 [email protected]